Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG, and Medac signed an exclusive license and supply agreement for the marketing of both Ameluz and BF-RhodoLED in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland.
Under the terms of the agreement, Medac will make an immediate one-time upfront payment of EUR 50,000 to the Company, plus an additional one-time payment of EUR 150,000 following receipt of the drug’s reimbursement eligibility from the Polish health insurance providers. According to the agreement, Medac receives exclusive distribution rights for Poland. Once reimbursement eligibility has been granted in Poland, Biofrontera will supply Ameluz® to Medac at a fixed transfer price based on the expected net revenues.
Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG, commented, “We are pleased to have a strong partner on our side to offer photodynamic therapy for the treatment of actinic keratosis and basal cell carcinoma by using Ameluz® and the BF-RhodoLED® in Poland.”